Results 1–20 of 229 for pfizer

Backbench Business: GKN: Proposed Takeover by Melrose — [Graham Stringer in the Chair] (15 Mar 2018)

Adrian Bailey: My experience of parliamentary scrutiny of takeover bids, from Kraft and Cadbury to Pfizer and AstraZeneca and, I hope, this one, is that, irrespective of the outcome, the fact that Parliament has scrutinised it has benefited the outcome—first, by holding the Government to account, and secondly, by holding the participant companies to account. I make no apologies for having the debate,...

Written Answers — Department of Health and Social Care: Pneumococcal Diseases: Vaccination (6 Mar 2018)

Steve Brine: As part of a stakeholder consultation on the childhood pneumococcal vaccination schedule, responses were sought from Pfizer, GlaxoSmithKline, Merck, Meningitis Now, and the Meningitis Research Foundation. The Joint Committee on Vaccination and Immunisation discussed the consultation responses at its meeting on 7 February and is continuing to consult on and review its advice.

Written Answers — Department of Health and Social Care: Alzheimer's Disease and Parkinson's Disease (24 Jan 2018)

the Marquess of Lothian: To ask Her Majesty's Government what steps they are taking to support research and drug development for Alzheimer’s and Parkinson’s disease; and what assessment they have made of Pfizer’s recent decision to end funding for research into both diseases.

Written Answers — Department for International Trade: Overseas Trade (18 Jan 2018)

Baroness Fairhead: ...Matthey Lockheed Martin Microsoft Mitsubishi Corporation Mitsubishi Heavy Industries Mondelez International National Grid Plc Nestle Nissan Novartis PCCW Pearson PepsiCo Pfizer Procter & Gamble (P&G) PSA Roche Group Rolls-Royce Group plc Royal Dutch Shell Plc RWE Sage Group Samsung Saudi Basic Industries (SABIC) Scottish & Southern...

Previous Business – Lords: Select Committee (28 Nov 2017)

Science and Technology Committee (Lords): Life Sciences and the Industrial Strategy. 10:00 am; Room 4A, Palace of Westminster
Witnesses: ...Westwood, Professor of Government Practice and Vice Dean of Humanities, Manchester University, Industrial Strategy Commission (at 11:00 AM) Mr Erik Nordkamp, Chair, American Pharmaceutical Group, Pfizer Mr Mark Hicken, Vice Chair, American Pharmaceutical Group, Janssen Ms Louise Houson, UK Managing Director, MSD

International Investment (17 Oct 2017)

Vincent Cable: ...some disappointment that his definition of it does not appear to include cases where British companies that are fundamental to the science base would be at risk of acquisition, as in the abortive Pfizer AstraZeneca bid, and more recently in the successful bid for ARM, Aveco and the many smaller companies now being acquired on the back of a cheap patent.

Written Answers — Department of Health: Piperacillin-tazobactam (10 Jul 2017)

Steve Brine: The Department is in direct contact with all suppliers of piperacillin-tazobactam about future supplies coming into the United Kingdom, including Pfizer who market the brand Tazocin. Pfizer currently have supplies available and have confirmed that they are able to bring larger volumes of Tazocin to the UK market from October onwards. Several other suppliers of generic piperacillin-tazobactam...

Economy and Jobs (29 Jun 2017)

Vincent Cable: chains. Are those going to continue? Another area in which the Prime Minister made a very helpful intervention was in suggesting that we need to look again at the takeover rules for companies, because we had a near miss with the Pfizer takeover which fell through, and which we discouraged. We need to strengthen the rules to protect our science base, but nothing in the Queen’s...

Written Answers — Department of Health: Epilepsy: Drugs (14 Mar 2017)

Alex Chalk: To ask the Secretary of State for Health, whether the Government is able to allocate Competition and Markets Authority fines collected from pharmaceutical manufacturers Pfizer and distributor Flynn Pharma for the purposes of research and treatment for epilepsy patients.

O’Neill Review — [Mr Gary Streeter in the Chair] (7 Mar 2017)

Kevin Hollinrake: ...return, it is difficult for pharmaceutical companies to invest in this field, although some are. For example, AstraZeneca recently sold its late-stage small molecule antibiotic business to Pfizer and so stepped out of research and development, but others, such as MSD, are still investing. It cannot be right that some companies are willing to invest—perhaps for altruistic...

Written Answers — Department of Health: Palbociclib (23 Feb 2017)

Simon Burns: To ask the Secretary of State for Health, what meetings representatives from NICE (a) have had and (b) plan to have with Pfizer during the consultation period for palbociclib (Ibrance) since the publication of the draft guidance on that drug on 3 February 2017.

Health Service Medical Supplies (Costs) Bill - Report (7 Feb 2017)

Lord Warner: ...I fully support the Government acting through the Bill to prevent the NHS being blatantly ripped off under the statutory scheme when a branded drug comes off patent, as happened with Flynn Pharma when a Pfizer anti-epilepsy drug came off patent. The ABPI has never challenged actions in cases of this kind. However, the broad wording of the Bill goes well beyond closing this particular...

Oral Answers to Questions — Treasury: Single Market (17 Jan 2017)

Julian Brazier: ...welcome my hon. Friend’s typically constructive approach, but does she recall the clinical trials directive that destroyed much of the pharmaceutical industry in this country overnight, including Pfizer’s site in east Kent?

Health Service Medical Supplies (Costs) Bill - Second Reading (21 Dec 2016)

Lord Hunt of Kings Heath: ...O’Shaughnessy, to his new post. He will enjoy taking the Bill through its remaining stages—perhaps. As noble Lords have said, the recent fines imposed by the Competition and Markets Authority on Pfizer and Flynn Pharma for charging the NHS excessive prices is a salutary warning to the pharmaceutical industry. We certainly welcome the provisions in the Bill that deal with the...

Public Bill Committee: Health Service Medical Supplies (Costs) Bill: Review of extending provisions to repurposed off-patent drugs (15 Nov 2016)

Philippa Whitford: pregabalin. The commonest use of that is for neuropathic pain: people who have had nerve damage from surgery or trauma and have difficult-to-control pain. The drug was originally designed for epilepsy, and Pfizer, which makes it, managed to get a court order saying that the patent on its use for neuropathic pain would continue to 2017 and that it would sue general practitioners who...

Drug-Resistant Infections - Motion to Take Note (15 Sep 2016)

Lord Hunt of Kings Heath: ...say a little more about the progress that is being made in those discussions? Vaccines have been mentioned by a number of noble Lords. I have had a comment from one of the companies that have briefed me—it was from Pfizer, in fact—that while the UK is a world leader in national immunisation programmes, its sense is that immunisation is not regarded by the Government as an,...

Previous Business – Commons: Select Committee (14 Sep 2016)

Sub-Committee on Education, Skills and the Economy: Apprenticeships. 2:15 pm; Room 16, Palace of Westminster
Witnesses: ...and Skills, British Chambers of Commerce Iain Murray, Senior Policy Officer, TUC Ben Willmott, Head of Public Policy, Chartered Institute of Personnel and Development Liz Greenfield, Head of HR, Pfizer Councillor Robert Light, Vice Chair of City Regions Board, Local Government Association Iain McIlwee, Chief Executive, British Woodworking Federation

Teachers: Academies and Free Schools - Question for Short Debate (12 Sep 2016)

Lord Suri: ...our economic future. In order to provide the best technical education, these schools need to attract the best talent from our universities and firms. For a young graduate who may have offers from, say, Rolls-Royce or Pfizer, having to go through the route of getting another degree may turn them off the profession altogether. Surely noble Lords will see the foolishness of such a move. I...

Fourth Industrial Revolution (8 Sep 2016)

Stephen Kinnock: view, we need to reform the Companies Act, placing a clear national interest clause and a method of monitoring and executing that clause, so that we move away from situations such as we saw with Pfizer attempting to take AstraZeneca. I am very thankful that the previous Leader of the Opposition did a great job in preventing that from happening, but it is very ad hoc and we need a...

Written Answers — Department of Health: NHS: Drugs (13 Jun 2016)

Alistair Burt: ...Ltd CM/PHR/10/5203 Pan London Antiretroviral 2013 Gilead Sciences Ltd CM/PHR/10/5203 Pan London Antiretroviral 2014 Gilead Sciences Ltd CM/PHR/10/5203 Pan London Antiretroviral 2015 Pfizer Limited CM/PHR/13/5415 Branded Pharmaceutical Products - National (05-2014) Source: Department of Health Commercial Medicines Unit 1 Based on pre-agreement estimated values for framework...

1 2 3 4 5 6 7 8 9 10 > >>

Create an alert

Did you find what you were looking for?

Advanced search

Find this exact word or phrase

You can also do this from the main search box by putting exact words in quotes: like "cycling" or "hutton report"

By default, we show words related to your search term, like “cycle” and “cycles” in a search for cycling. Putting the word in quotes, like "cycling", will stop this.

Excluding these words

You can also do this from the main search box by putting a minus sign before words you don’t want: like hunting -fox

We also support a bunch of boolean search modifiers, like AND and NEAR, for precise searching.

Date range


You can give a start date, an end date, or both to restrict results to a particular date range. A missing end date implies the current date, and a missing start date implies the oldest date we have in the system. Dates can be entered in any format you wish, e.g. 3rd March 2007 or 17/10/1989


Enter a name here to restrict results to contributions only by that person.


Restrict results to a particular parliament or assembly that we cover (e.g. the Scottish Parliament), or a particular type of data within an institution, such as Commons Written Answers.


If you know the actual Hansard column number of the information you are interested in (perhaps you’re looking up a paper reference), you can restrict results to that; you can also use column:123 in the main search box.